摘要
目的研究辉瑞公司专利产出与经济产出的相关性,分析该公司专利分布及保护情况。方法运用相关回归方法,研究2000~2010年辉瑞公司的全球专利申请数与经济产出（年销售收入/净利润）的相关性,统计分析了该公司中国专利分布情况及上市品种中4种药物阿托伐他汀钙（立普妥）、阿奇霉素（希舒美）、苯磺酸氨氯地平（络活喜）和盐酸舍曲林（左洛复）的专利保护情况。结果①辉瑞公司专利产出与经济收入成正相关,回归方程有良好的线性关系,方差分析具显著性;②辉瑞公司中国专利中以发明专利为主,专利授权率只有10%;③辉瑞公司无论是全球专利申请量还是中国专利申请量已呈逐年减少趋势;④专利对其上市药物保护作用明显,在专利保护期内销售收入呈现较大辐度增长,随着专利到期销售收入呈下滑趋势。结论专利保护战略能促进跨国公司创造重磅炸弹级药物,并为其带来巨大经济效益;研发新药费用剧增导致跨国公司新药创制减缓;科技创新及其专利保护是跨国公司在竞争中的重要武器,国内政府部门和医药企业应积极应对。
Objective To determine the relationship between the patent output and the economxc output, ana anatyze the distribution and the protection of patents. Methods Using the relevant regression method, we analyzed the rela- tionship between the patent output and the economic output and the distribution of Chinese patents in Pfizer from 2000 to 2010, in which the patent influenced the economic output in 4 drug ＂blockbusters＂, i.e. Lipitor （Atorvastatin）, Zithromax （Azithromycin）, Norvasc （Amlodipine besylate） and Zoloft （Sertraline hydrochloride）. Results ① There was a positive equation and a positive correlation between the patent output and the economic efficiency in Pfizer; ② Most China patents were patent of invention, in which the grant ratio of invention patents was 10%;③The patent ap- plication number went down every year at home and abroad;④Patent protectd the drug ＂blockbuster＂ that brought much profit to Pfizer. Conclusion The protection of intellectual property rights may cause the international corporation to make drug ＂blockbusters＂ that will bring huge economic profit. The high expense decreased the invention pace of drugs in international corporations. Technological innovation and intellectual property protection are the most impor- tant weapons in the fierce competition. The governments and enterprises should respond to the challenge actively.
出处
《中南药学》
CAS
2011年第6期467-470,共4页
Central South Pharmacy
基金
湖南省知识产权局软课题(HNR2010208)
